BREAKING NEWS
Cloud Server Hosting For Online Businesses
Inexpensive SEO Services
Benefits of Wanting to play Free Online Slot machines
Farglitazar

Summary

Farglitazar is a peroxisome proliferator-activated receptor agonist which was formerly under development by GlaxoSmithKline, but has never been marketed. It progressed to phase II clinical trials for the treatment of hepatic fibrosis, but failed to show efficacy.[1] After reaching phase III for type 2 diabetes, further development was discontinued.[2][3]

Farglitazar
Clinical data
Pregnancy
category
  • N/A
ATC code
  • none
Legal status
Legal status
  • Development discontinued
Identifiers
  • N-(o-Benzoylphenyl)-O-[2-(5-methyl- 2-phenyl-4-oxazolyl)ethyl]-L-tyrosine
CAS Number
  • 196808-45-4 checkY
PubChem CID
  • 170364
IUPHAR/BPS
  • 2672
ChemSpider
  • 148961 checkY
UNII
  • 3433GY7132
KEGG
  • D04132
ChEMBL
  • ChEMBL107367 checkY
CompTox Dashboard (EPA)
  • DTXSID1047310 Edit this at Wikidata
Chemical and physical data
FormulaC34H30N2O5
Molar mass546.623 g·mol−1
3D model (JSmol)
  • Interactive image
  • O=C(c1ccccc1)c2ccccc2N[C@H](C(=O)O)Cc5ccc(OCCc3nc(oc3C)c4ccccc4)cc5
  • InChI=1S/C34H30N2O5/c1-23-29(36-33(41-23)26-12-6-3-7-13-26)20-21-40-27-18-16-24(17-19-27)22-31(34(38)39)35-30-15-9-8-14-28(30)32(37)25-10-4-2-5-11-25/h2-19,31,35H,20-22H2,1H3,(H,38,39)/t31-/m0/s1 ☒N
  • Key:ZZCHHVUQYRMYLW-HKBQPEDESA-N ☒N
 ☒NcheckY (what is this?)  (verify)

References edit

  1. ^ McHutchison J, Goodman Z, Patel K, Makhlouf H, Rodriguez-Torres M, Shiffman M, et al. (April 2010). "Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection". Gastroenterology. 138 (4): 1365–73, 1373.e1-2. doi:10.1053/j.gastro.2009.12.003. PMID 20004661.
  2. ^ "Farglitazar". Adis Insight. Springer Nature Switzerland AG.
  3. ^ "Farglitazar". pharmacodia.com.